Cancer is still the most common cause of death for men in the US ages 60 to 79 and women ages 40 to 79. For all adults ...

A new long-term prediction tool estimates the risk of dying from prostate cancer, offering a more accurate way to interpret ...

In this cohort study, a novel prognostic model was developed to estimate prostate cancer-specific mortality (PCSM) while ...

Men treated for nonmetastatic prostate cancer under current guidelines are up to 6 times less likely to die from their cancer than from other causes, according to data from a Swedish cancer registry.

A new combination of drugs could help delay the advancement of a deadly form of prostate cancer in those with an advanced form of the disease, new research has found. The “striking” findings showed an ...

PLYMOUTH MEETING, PA [July 10, 2025] — New research in the July 2025 issue of JNCCN—Journal of the National Comprehensive Cancer Network finds that for people diagnosed with nonmetastatic low-risk ...

Most men who are treated for prostate cancer according to modern guidelines have good survival rates and the majority of these men will die of causes other than prostate cancer. This is revealed in a ...

What are the current prostate cancer screening guidelines and treatment recommendations? Men may be offered prostate cancer screening at different life stages depending on their individual risk. Age, ...

The European Randomized Study of Screening for Prostate Cancer (ERSPC) was initiated in 1993 to assess the effect of prostate-specific antigen (PSA) testing on prostate cancer mortality. Because ...

That’s because most cases are caught before the cancer has spread. In fact, more than 75% of diagnoses are made while the disease is still confined to the prostate. When that happens, the outlook is ...